See more : Kawasaki Kisen Kaisha, Ltd. (KAIKY) Income Statement Analysis – Financial Results
Complete financial analysis of NGM Biopharmaceuticals, Inc. (NGM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NGM Biopharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- HSINO TOWER GROUP CO LTD (601096.SS) Income Statement Analysis – Financial Results
- Agree Realty Corporation (ADC-PA) Income Statement Analysis – Financial Results
- Fortress Value Acquisition Corp. IV (FVIV) Income Statement Analysis – Financial Results
- Glen Rose Petroleum Corporation (GLRP) Income Statement Analysis – Financial Results
- Vishwaraj Sugar Industries Limited (VISHWARAJ.NS) Income Statement Analysis – Financial Results
NGM Biopharmaceuticals, Inc. (NGM)
About NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.42M | 55.33M | 77.88M | 87.37M | 103.54M | 108.67M | 77.14M | 85.59M |
| Cost of Revenue | 2.22M | 5.98M | 7.90M | 163.97M | 129.25M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.20M | 49.35M | 69.98M | -76.60M | -25.71M | 108.67M | 77.14M | 85.59M |
| Gross Profit Ratio | 49.72% | 89.19% | 89.86% | -87.68% | -24.83% | 100.00% | 100.00% | 100.00% |
| Research & Development | 112.01M | 181.07M | 161.71M | 163.97M | 129.25M | 95.71M | 79.74M | 82.11M |
| General & Administrative | 37.84M | 40.52M | 36.87M | 27.23M | 23.63M | 17.27M | 14.83M | 11.85M |
| Selling & Marketing | -1.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 36.74M | 40.52M | 36.87M | 27.23M | 23.63M | 17.27M | 14.83M | 11.85M |
| Other Expenses | -234.00K | -132.00K | -60.00K | -593.00K | -147.00K | 199.00K | -152.00K | 133.00K |
| Operating Expenses | 148.74M | 221.58M | 198.58M | 191.20M | 152.88M | 112.98M | 94.57M | 93.95M |
| Cost & Expenses | 150.96M | 221.58M | 198.58M | 191.20M | 152.88M | 112.98M | 94.57M | 93.95M |
| Interest Income | 9.32M | 3.71M | 420.00K | 1.94M | 6.69M | 3.62M | 2.36M | 1.81M |
| Interest Expense | 0.00 | 3.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.22M | 4.04M | 6.09M | 6.56M | 7.61M | 7.22M | 6.44M | 3.53M |
| EBITDA | -144.33M | -166.25M | -120.70M | -103.83M | -49.34M | 2.91M | -10.98M | -4.83M |
| EBITDA Ratio | -3,267.51% | -300.45% | -154.97% | -118.85% | -47.65% | 2.68% | -14.24% | -5.64% |
| Operating Income | -146.55M | -166.25M | -120.70M | -103.83M | -49.34M | -4.31M | -17.43M | -8.36M |
| Operating Income Ratio | -3,317.79% | -300.45% | -154.97% | -118.85% | -47.65% | -3.97% | -22.59% | -9.77% |
| Total Other Income/Expenses | 4.17M | 3.58M | 360.00K | 1.35M | 6.55M | 3.82M | 2.21M | 1.94M |
| Income Before Tax | -142.38M | -162.67M | -120.34M | -102.49M | -42.80M | -493.00K | -15.22M | -6.42M |
| Income Before Tax Ratio | -3,223.34% | -293.98% | -154.51% | -117.30% | -41.33% | -0.45% | -19.73% | -7.50% |
| Income Tax Expense | 0.00 | -3.58M | -6.51M | -8.49M | -14.30M | 3.82M | -1.06M | 500.00K |
| Net Income | -142.38M | -159.09M | -113.83M | -93.99M | -28.50M | -493.00K | -14.16M | -6.92M |
| Net Income Ratio | -3,223.34% | -287.50% | -146.15% | -107.58% | -27.52% | -0.45% | -18.35% | -8.09% |
| EPS | -1.73 | -1.99 | -1.48 | -1.37 | -0.57 | -0.01 | -0.26 | -0.13 |
| EPS Diluted | -1.73 | -1.99 | -1.48 | -1.37 | -0.57 | -0.01 | -0.26 | -0.13 |
| Weighted Avg Shares Out | 82.50M | 79.95M | 77.09M | 68.48M | 50.30M | 64.99M | 53.65M | 53.65M |
| Weighted Avg Shares Out (Dil) | 82.50M | 79.95M | 77.09M | 68.48M | 50.30M | 64.99M | 53.65M | 53.65M |
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Why NGM Biopharmaceuticals Dived by 41% on Monday
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Analyst Reactions on NGM Biopharmaceuticals Disappointing Aldafermin Data in NASH Study
Why Scopus, NGM Biopharma and Taiwan Liposome Are Moving Today
NGM Stock Price: Over 40% Decrease Pre-Market Explanation
NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Tops Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports